Bristol’s bad news is good for rivals: analysts
August 02, 2012 at 17:51 PM EDT
Bristol-Myers Squibb’s hepatitis C drug INX-189 might be a dud, but that may be a boon for rival drug developers, analysts say.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|